Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• SantarpiaMKarachaliouNRosellRBeyond platinum treatment for NSCLC: what does the future hold?Expert Rev Anticancer Ther201717429329528129003
   PubMed Web of Science ®Google Scholar
• RosellRKarachaliouNLarge-scale screening for somatic mutations in lung cancerLancet2016387100261354135626777918
   PubMed Web of Science ®Google Scholar
• LazzariCSpitaleriGCataniaCTargeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic optionsCrit Rev Oncol Hematol201489335836524156959
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213239246
   Web of Science ®Google Scholar
• HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol2013241545922967997
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCHYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• BlackhallFCappuzzoFCrizotinib: from discovery to accelerated development to front-line treatmentAnn Oncol201627Suppl 3iii35iii4127573754
   PubMed Web of Science ®Google Scholar
• NovelloSBarlesiFCalifanoRCuferTMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• SetoTKatoTNishioMErlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncol201415111236124425175099
   PubMed Web of Science ®Google Scholar
• RosellRDafniUFelipEErlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialLancet Respir Med20175543544428408243
   PubMed Web of Science ®Google Scholar
• WuJSavoojiJLiuDSecond- and third-generation ALK inhibitors for non-small cell lung cancerJ Hematol Oncol2016911926951079
   PubMed Web of Science ®Google Scholar
• SantarpiaMDaffinàMGD’AveniASpotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapyDrug Des Dev Ther20171120472063
   PubMed Web of Science ®Google Scholar
• SantarpiaMAltavillaGRosellRAlectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancerExpert Rev Respir Med20159325526825652176
   PubMed Web of Science ®Google Scholar
• PlanchardDBesseBGroenHJDabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialLancet Oncol201617798499327283860
   PubMed Web of Science ®Google Scholar
• SantarpiaMGiovannettiERolfoCRecent developments in the use of immunotherapy in non-small cell lung cancerExpert Rev Respir Med201610778179827148808
   PubMed Web of Science ®Google Scholar
• KarachaliouNSosaAEBarronFBPharmacological management of relapsed/refractory NSCLC with chemical drugsExpert Opin Pharmacother201718329530428103738
   PubMed Web of Science ®Google Scholar
• ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med20163751823183327718847
   PubMed Web of Science ®Google Scholar
• DholariaBHammondWShredersALouYEmerging therapeutic agents for lung cancerJ Hematol Oncol20169113827938382
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGEGFR antagonist in cancer treatmentN Engl J Med2008358111160117418337605
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
   PubMed Web of Science ®Google Scholar
• HirschFRVarella-GarciaMBunnPAJrEpidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosisJ Clin Oncol200321203798380712953099
   PubMed Web of Science ®Google Scholar
• KrisMGJohnsonBEBerryLDUsing multiplexed assays of oncogenic drivers in lung cancers to select targeted drugsJAMA2014311191998200624846037
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibNew Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• ZhangYLYuanJQWangKFThe prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysisOncotarget2016748789857899327738317
   PubMedGoogle Scholar
• GreenhalghJDwanKBolandAFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerCochrane Database Syst Rev20165CD01038327223332
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAisnerDLNon-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncologyJ Natl Compr Canc Netw201715450453528404761
   PubMed Web of Science ®Google Scholar
• SantarpiaMGilNRosellRStrategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancerExpert Rev Clin Pharmacol20158446147726068305
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• TanCSGilliganDPaceySTreatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancerLancet Oncol2015169e447e45926370354
   PubMed Web of Science ®Google Scholar
• KochHBustoMEKramerKChemical proteomics uncovers EPHA2 as a mechanism of acquired resistance to small molecule EGFR kinase inhibitionJ Proteome Res20151462617262525963923
   PubMed Web of Science ®Google Scholar
• BivonaTGHieronymusHParkerJFAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFRNature2011471733952352621430781
   PubMed Web of Science ®Google Scholar
• KarachaliouNCodony-ServatJTeixidóCBIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerSci Rep201551749926639561
   PubMed Web of Science ®Google Scholar
• LeeHJZhuangGCaoYDrug resistance via feedback activation of stat3 in oncogene-addicted cancer cellsCancer Cell201426220722125065853
   PubMed Web of Science ®Google Scholar
• GandaraDRLiTLaraPNAcquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implicationsClin Lung Cancer20141511624176733
   PubMed Web of Science ®Google Scholar
• YuHASimaCSHuangJLocal therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitorsJ Thorac Oncol20138334635123407558
   PubMed Web of Science ®Google Scholar
• ConfortiFCataniaCToffalorioFEGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungLung Cancer201381344044423810573
   PubMed Web of Science ®Google Scholar
• SoriaJCWuYLNakagawaKGefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncol201516899099826159065
   PubMed Web of Science ®Google Scholar
• SoriaJCKimSWWuYLGefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): final overall survival (OS) analysisAnn Oncol201627Suppl 6vi416vi454
   Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA200810562070207518227510
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKGaleCMPF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res20076724119241193218089823
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• KwakEThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerOncologist201116111498150722016476
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
   PubMed Web of Science ®Google Scholar
• EllisPMShepherdFAMillwardMDacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trialLancet Oncol201415121379138825439692
   PubMed Web of Science ®Google Scholar
• SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
   PubMed Web of Science ®Google Scholar
• JanjigianYYSmitEFGroenHJDual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsCancer Discov2014491036104525074459
   PubMed Web of Science ®Google Scholar
• ZhouWJErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature200946272761070107420033049
   PubMed Web of Science ®Google Scholar
• RielyGJYuHAEGFR: the paradigm of an oncogene-driven lung cancerClin Cancer Res201521102221222625979928
   PubMed Web of Science ®Google Scholar
• WalterAOSjinRTHaringsmaHJDiscovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCCancer Discov20133121404141524065731
   PubMed Web of Science ®Google Scholar
• CrossDAAshtonSEGhiorghiuSAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerCancer Discov2014491046106124893891
   PubMed Web of Science ®Google Scholar
• SequistLVSoriaJCGoldmanJWRociletinib in EGFR-mutated non-small-cell lung cancerN Engl J Med2015372181700170925923550
   PubMed Web of Science ®Google Scholar
• JännePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• Van Der SteenNCaparelloCRolfoCNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Onco Targets Ther201696065607427785053
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves new pill to treat certain patients with non-small cell lung cancer2015 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htmAccessed May 15, 2017
   Google Scholar
• HiranoTYasudaHTaniTIn vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerOncotarget2015636387893880326515464
   PubMed Web of Science ®Google Scholar
• PlanchardDBrownKHKimD-WOsimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studiesCancer Chemother Pharmacol201677476777626902828
   PubMed Web of Science ®Google Scholar
• GossGTsaiCMShepherdFAOsimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyLancet Oncol201617121643165227751847
   PubMed Web of Science ®Google Scholar
• TAGRISSO® (osimertinib) tablets, for oral use. US prescribing information2015 Available from:https://www.accessdata.fda.gov/drug-satfda_docs/label/2017/208065s006lbl.pdfAccessed May 15, 2017
   Google Scholar
• YangJCAhnMJKimDWOsimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension ComponentJ Clin Oncol201735121288129628221867
   PubMed Web of Science ®Google Scholar
• YangJRamalingamSSJännePALBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) resultsJ Thorac Oncol2016114S152S153
   Web of Science ®Google Scholar
• MokTSWuY-LAhnM-JOsimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancerN Engl J Med2017376762964027959700
   PubMed Web of Science ®Google Scholar
• ParkSJKimHTLeeDHEfficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutationLung Cancer201277355656022677429
   PubMed Web of Science ®Google Scholar
• HoffknechtPTufmanAWehlerTEfficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated nonsmall-cell lung cancer patients with brain metastases or leptomeningeal diseaseJ Thorac Oncol201510115616325247337
   PubMed Web of Science ®Google Scholar
• AltavillaGArrigoCSantarpiaMCErlotinib therapy in a patient with non-small-cell lung cancer and brain metastasesJ Neurooncol2008901313318566747
   PubMed Web of Science ®Google Scholar
• ProtoCImbimboMGallucciREpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the futureTransl Lung Cancer Res20165656357828149752
   PubMed Web of Science ®Google Scholar
• ClarkeJLPaoWWuNHigh dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJ Neurooncol201099228328620146086
   PubMed Web of Science ®Google Scholar
• GrommesCOxnardGRKrisMG“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerNeuro Oncol201113121364136921865399
   PubMed Web of Science ®Google Scholar
• TogashiYMasagoKFukudoMEfficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutationCancer Chemother Pharmacol20116841089109221681573
   PubMed Web of Science ®Google Scholar
• MiltonDTAzzoliGCHeelanRTA phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerCancer200610751034104116878326
   PubMed Web of Science ®Google Scholar
• HeonSYeapBYBrittGJDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinibClin Cancer Res2010165873588221030498
   PubMed Web of Science ®Google Scholar
• ZimmermannSDziadziuszkoRPetersSIndications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastasesCancer Treat Rev201440671672224759599
   PubMed Web of Science ®Google Scholar
• BallardPYatesJWYangZPreclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activityClin Cancer Res201622205130514027435396
   PubMed Web of Science ®Google Scholar
• GossGTsaiCShepherdFCNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsIALSC Congress2016 MA16.11
   Google Scholar
• PareekVWelchMRaveraEMarked differences in CNS activity among EGFR inhibitors: case report and mini-reviewJ Thorac Oncol20161111e135e13927464969
   PubMed Web of Science ®Google Scholar
• YangJCHKimDWKimSWOsimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I studyJ Clin Oncol201634Suppl abstr9002
   Google Scholar
• AhnMJKimDWKimTMPhase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)J Clin Oncol201634 abstr 9003
   Web of Science ®Google Scholar
• SantarpiaMKarachaliouNGonzález-CaoMFeasibility of cell-free circulating tumor DNA testing for lung cancerBiomark Med201610441743026974841
   PubMed Web of Science ®Google Scholar
• TaniguchiKUchidaJNishinoKQuantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomasClin Cancer Res201117247808781521976538
   PubMed Web of Science ®Google Scholar
• OxnardGRPaweletzCPKuangYNoninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNAClin Cancer Res20142061698170524429876
   PubMed Web of Science ®Google Scholar
• SundaresanTKSequistLVHeymachJVDetection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analysesClin Cancer Res20162251103111026446944
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRSAssociation between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancerJ Clin Oncol201634283375338227354477
   PubMed Web of Science ®Google Scholar
• RemonJCaramellaCJoveletCOsimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNAAnn Oncol201728478479028104619
   PubMed Web of Science ®Google Scholar
• BuderAHochmairMHolzerSAssociation between EGFR T790M mutation copy numbers in cell-free plasma DNA and response to osimertinib in advanced NSCLCJ Thor Oncol2017121SS1206
   Google Scholar
• SullivanIPlanchardDOsimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experienceTher Adv Respir Dis201610654956527784815
   PubMed Web of Science ®Google Scholar
• WangSSongYYanFLiuDMechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFront Med201610438338827770386
   PubMed Web of Science ®Google Scholar
• ThressKSPaweletzCPFelipEAcquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MNat Med201521656056225939061
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol2016915927448564
   PubMed Web of Science ®Google Scholar
• ErcanDChoiHGYunCHEGFR mutations and resistance to irreversible pyrimidine- based EGFR inhibitorsClin Cancer Res201521173913392325948633
   PubMed Web of Science ®Google Scholar
• NiederstMJHuHMulveyHEThe allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategiesClin Cancer Res201521173924393325964297
   PubMed Web of Science ®Google Scholar
• RosellRKarachaliouNLung cancer: using ctDNA to track EGFR and KRAS mutations in advanced-stage diseaseNat Rev Clin Oncol201613740140227245284
   PubMed Web of Science ®Google Scholar
• SongHNJungKSYooKHAcquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancerJ Thorac Oncol2016114e45e4726749488
   PubMed Web of Science ®Google Scholar
• ChabonJJSimmonsADLovejoyAFCirculating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patientsNat Commun201671181527283993
   PubMed Web of Science ®Google Scholar
• OuSICuiJSchrockABEmergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibLung Cancer201710822823128625641
   PubMed Web of Science ®Google Scholar
• NukagaSYasudaHTsuchiharaKAmplification of EGFR wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitorsCancer Res20177782078208928202511
   PubMed Web of Science ®Google Scholar
• ChaibIKarachaliouNPilottoSCo-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLCJ Natl Cancer Inst20171099
   PubMedGoogle Scholar
• ZhangJJiJYYuMYAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathwayNat Cell Biol200911121444145019935651
   PubMed Web of Science ®Google Scholar
• EberleinCAStetsonDMarkovetsAAAcquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical modelsCancer Res201575122489250025870145
   PubMed Web of Science ®Google Scholar
• TrickerEMXuCUddinSCombined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancerCancer Discov20155996097126036643
   PubMed Web of Science ®Google Scholar
• HoCCLiaoWYLinCAAcquired BRAF V600E mutation as resistant mechanism after treatment with osimertinibJ Thorac Oncol201712356757227923714
   PubMed Web of Science ®Google Scholar
• PlanchardDLoriotYAndreFEGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patientsAnn Oncol201526102073207826269204
   PubMed Web of Science ®Google Scholar
• OuSHAgarwalNAliSMHigh MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progressionLung Cancer201698596127393507
   PubMed Web of Science ®Google Scholar
• Ortiz-CuaranSSchefflerMPlenkerDHeterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitorsClin Cancer Res201622194837484727252416
   PubMed Web of Science ®Google Scholar
• HamJSKimSKimHKTwo cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatmentJ Thorac Oncol2016111e1e426762749
   PubMed Web of Science ®Google Scholar
• RamalingamSYangJCLeeCKOsimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohortsJ Thorac Oncol2016114 SupplS152
   Web of Science ®Google Scholar
• DenisMGValléeAThéoleyreSEGFR T790M resistance mutation in non small-cell lung carcinomaClin Chim Acta2015444818525668228
   PubMed Web of Science ®Google Scholar
• SuKYChenHYLiKCPretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerJ Clin Oncol201230443344022215752
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMEHellmannMDPoor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingAnn Oncol201425242342824478319
   PubMed Web of Science ®Google Scholar
• LeeYLeeGKLeeYSClinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutationsCancer2014120142090209824737599
   PubMed Web of Science ®Google Scholar
• CostaCMolinaMADrozdowskyjAThe impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialClin Cancer Res20142072001201024493829
   PubMed Web of Science ®Google Scholar
• DiggsLPHsuehECUtility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor responseBiomarker Res20175112
   Web of Science ®Google Scholar
• GarassinoMChoBGrayJEDurvalumab in ≥ 3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: results from the phase 2 ATLANTIC studyAnn Oncol201728Suppl 2ii28ii51
   Google Scholar
• AhnMJYangJYuHOsimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trialJ Thorac Oncol2016114S115
   PubMed Web of Science ®Google Scholar
• PlanchardDKrisMBesseBPhase 1 study of ramucirumab or necitumumab in combination with osimertinib (AZD9291) in advanced T790M-positive EGFR-mutant NSCLCJ Thor Oncol2017121S1071(P2.06–005)
   Web of Science ®Google Scholar
• HataANNiederstMJArchibaldHLTumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionNat Med201622326226926828195
   PubMed Web of Science ®Google Scholar
• JiaYYunCHParkEOvercoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitorsNature2016534760512913227251290
   PubMed Web of Science ®Google Scholar
• WangSSongYLiuDEAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistanceCancer Lett2017385515427840244
   PubMed Web of Science ®Google Scholar
• UchiboriKInaseNArakiMBrigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerNat Commun201781476828287083
   PubMed Web of Science ®Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol2016913427071706
   PubMed Web of Science ®Google Scholar
• BarnesTAO’KaneGMVincentMDLeighlNBThird-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancerFront Oncol2017711328620581
   PubMed Web of Science ®Google Scholar
• TanDSWYangJCHLeighlNBUpdated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790MJ Clin Oncol201634Suppl abstr 9044
   Google Scholar
• YuHASpiraAIHornLAntitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: interim results from an ongoing phase 1 studyJ Clin Oncol201634 abstr 9050
   Web of Science ®Google Scholar
• XuXMaoLXuWAC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patientsMol Cancer Ther201615112586259727573423
   PubMed Web of Science ®Google Scholar
• HusainHMartinsRGoldbergSPhase 1 dose escalation of PF-06747775 (EGFR-T790M inhibitor) in patients with advanced EGFRm (Del 19 or L858R+/-T790M) NSCLCJ Thor Oncol2017121S1185
   Web of Science ®Google Scholar
• YuHASpiraAIHornLAntitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: interim results from an ongoing phase 1 studyJ Clin Oncol201634Suppl abstr 9050
   Google Scholar
• ReckampKLMelnikovaVOKarlovichCA highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasmaJ Thorac Oncol201611101690170027468937
   PubMed Web of Science ®Google Scholar